Gilead Sciences Inc. is exploring ways to make its experimental Covid-19 medicine more broadly available, potentially treating patients in the outpatient setting, the company’s CEO said Friday.
Preliminary data released this week by the National Institutes of Health showed promising signs that remdesivir can speed up the recovery time for Covid-19 patients. But that study only tested the drug on the patients with a severe form of the disease, who received a daily infusion over 10 days. Daniel O’Day, Gilead’s CEO, said on NBC the company is looking at different ways of administering the medicine to make it available to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.